SCIO-469 Scios Inc

dc.contributor.author	Nikas, S. N.	en
dc.contributor.author	Drosos, A. A.	en
dc.date.accessioned	2015-11-24T18:52:53Z
dc.date.available	2015-11-24T18:52:53Z
dc.identifier.issn	1472-4472	-
dc.identifier.uri	https://olympias.lib.uoi.gr/jspui/handle/123456789/18449
dc.rights	Default Licence	-
dc.subject	Animals	en
dc.subject	Arthritis, Rheumatoid/drug therapy	en
dc.subject	Clinical Trials, Phase I as Topic	en
dc.subject	Clinical Trials, Phase II as Topic	en
dc.subject	Enzyme Inhibitors/metabolism/pharmacology/*therapeutic use	en
dc.subject	Humans	en
dc.subject	Indoles/metabolism/pharmacology/*therapeutic use	en
dc.subject	Structure-Activity Relationship	en
dc.subject	p38 Mitogen-Activated Protein Kinases/*antagonists & inhibitors	en
dc.title	SCIO-469 Scios Inc	en
heal.abstract	SCIO-469 is a small-molecule p38 mitogen-activated protein (MAP) kinase inhibitor under development by Scios Inc as a potential oral therapy for inflammatory disorders. By July 2004, SCIO-469 was in phase lib clinical trials for rheumatoid arthritis.	en
heal.access	campus	-
heal.fullTextAvailability	TRUE	-
heal.identifier.secondary	http://www.ncbi.nlm.nih.gov/pubmed/15573872	-
heal.journalName	Curr Opin Investig Drugs	en
heal.journalType	peer-reviewed	-
heal.language	en	-
heal.publicationDate	2004	-
heal.recordProvider	Πανεπιστήμιο Ιωαννίνων. Σχολή Επιστημών Υγείας. Τμήμα Ιατρικής	el
heal.type	journalArticle	-
heal.type.el	Άρθρο Περιοδικού	el
heal.type.en	Journal article	en

Αρχεία

Προβολή: 1 - 1 of 1